PLRXHealthcare · BiotechnologyThe 4 Wall Street analysts covering Pliant Therapeutics, Inc. hold a median 12-month price target of $2 — +132.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 31 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pliant Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (88): The share count has been shrinking and the company is not leaning on new borrowing.
Value (24): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PLRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +132.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | Canaccord Genuity | Maintains | Hold | $4.00 → $3.00 |
| 12 Mar 2026 | Piper Sandler | Maintains | Overweight | $4.00 → $3.00 |
| 7 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 10 Oct 2025 | JP Morgan | Downgrade | Underweight | — |
| 8 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 4 Mar 2025 | Cantor Fitzgerald | Reinstates | Neutral | — |
| 4 Mar 2025 | Citigroup | Maintains | Neutral | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 4 Mar 2025 | Needham | Downgrade | Hold | — |
| 4 Mar 2025 | RBC Capital | Maintains | Sector Perform | — |
| 4 Mar 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 3 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 14 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 14 Feb 2025 | Needham | Reiterates | Buy | — |
| 10 Feb 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 10 Feb 2025 | Citigroup | Downgrade | Neutral | — |
| 10 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 10 Feb 2025 | JP Morgan | Downgrade | Neutral | — |
| 10 Feb 2025 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Pliant Therapeutics, Inc. returned −47.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 85% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pliant Therapeutics, Inc. has a market value of $53.2M and an enterprise value of −$76.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.3M.
Diluted earnings per share, trailing twelve months: $−1.49.
Free cash flow in the twelve months to 30 June 2026: −$70.9M.
Trailing P/E: −0.4×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pliant Therapeutics, Inc. employs 49 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pliant Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pliant Therapeutics announced two presentations related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 4–8, 2026, in Phoenix, Arizona.
Why it matters — The presentations will share information about PLN-101095 at an upcoming scientific meeting.
Pliant Therapeutics appointed Craig Blanchette, Ph.D., as Senior Vice President, Research. The company described him as a leader in RNAi drug discovery with experience advancing delivery platforms and therapeutics.
Why it matters — The appointment is relevant to PLRX watchers because his experience is intended to support the company’s integrin-mediated delivery platform.
Pliant Therapeutics announced that it will present at the ESMO Congress 2026, scheduled for October 23–27 in Madrid. The presentation will feature FORTIFY, its ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors.
Why it matters — The presentation will provide an update on a Pliant clinical trial and its enrollment of patients with ICI-refractory solid tumors.
Pliant Therapeutics has appointed David Raben, M.D., as its Chief Medical Officer. Raben brings three decades of academic and biopharmaceutical oncology expertise as a leader in targeted immuno-oncology drug development.
Why it matters — A PLRX watcher would care because a new chief medical officer with deep oncology and drug-development experience may strengthen the company's clinical leadership and medical strategy.
Pliant Therapeutics announced that the FDA granted Fast Track designation to PLN-101095, an oral dual inhibitor of αvβ8 and αvβ1 integrins, when used in combination with pembrolizumab for the potential treatment of solid tumors resistant to immune checkpoint inhibitors.
Why it matters — The Fast Track designation may expedite development and review of PLN-101095 in combination with pembrolizumab, a key pipeline candidate for Pliant Therapeutics.
The 4 Wall Street analysts covering Pliant Therapeutics, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Pliant Therapeutics, Inc., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pliant Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Pliant Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (88 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +132.9% from the last close, and Ticker Nerd's factor model ranks Pliant Therapeutics, Inc. 73 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pliant Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
Pliant Therapeutics, Inc. returned -47.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer". Pliant Therapeutics announced two presentations related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 4–8, 2026, in Phoenix, Arizona.
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.
CEO Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. · 49 employees · United States · https://pliantrx.com
